<SEC-DOCUMENT>0001493152-22-036057.txt : 20230418
<SEC-HEADER>0001493152-22-036057.hdr.sgml : 20230418
<ACCEPTANCE-DATETIME>20221220201059
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-22-036057
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20221220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><IMG SRC="formdrsltr_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
20, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>VIA
EDGAR</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities &amp; Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, NE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
DC 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Office of Industrial Applications and Services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
    </FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
    No. 1 to Draft Registration Statement on Form S-1</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Submitted
    November 18, 2022</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CIK
    No. 0001938046</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Inc., a Texas corporation (the &ldquo;<U>Company</U>&rdquo;, &ldquo;<U>we</U>&rdquo;, &ldquo;<U>us</U>&rdquo; or &ldquo;<U>Mangoceuticals</U>&rdquo;),
would like to thank you for your prompt review of the Company&rsquo;s Amendment No. 1 to Draft Registration Statement on Form S-1, submitted
November 18, 2022 (the &ldquo;<U>Registration Statement</U>&rdquo;). We are responding to comments on the Registration Statement provided
by the staff (the &ldquo;<U>Staff</U>&rdquo;) of Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) by letter dated
December 8, 2022. In connection with these responses, we are submitting an Amendment No. 2 to the Draft Registration Statement on Form
S-1 (&ldquo;<U>Amendment No. 2</U>&rdquo;) via EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
responses to the Staff&rsquo;s comments are indicated below, directly following a restatement of each comment in bold type.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment
No. 1 to Draft Registration Statement on Form S-1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview,
page 1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1. We
note your revised disclosures in response to prior comment 3. Please remove statements on page 1 and elsewhere concerning the expectation
that your formulation may deliver &ldquo;fast acting results,&rdquo; that it may have a &ldquo;fast onset of action&rdquo; and that it
is not &ldquo;expected to have any material side effects.&rdquo; In this regard, efficacy and safety determinations are within the purview
of FDA and furthermore, based on your disclosures, there is no clinical trial data involving your formulation nor any indication that
a person has ever taken this formulation. You may indicate that the planned product employs a sublingual delivery mechanism because such
mechanisms generally allow for a faster rate of drug absorption without indicating that your planned drug has or may have the designed
effect. Also, remove or revise the statement on page 4 that claims such as &ldquo;fast acting results&rdquo; and &ldquo;fast onset of
action&rdquo; are not efficacy claims.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
The Company has revised the disclosures in Amendment No. 2 to remove all references to &ldquo;fast acting results,&rdquo; &ldquo;fast
onset of action&rdquo; and that our Mango ED product is not &ldquo;expected to have any material side effects&rdquo;, as well as similar
language.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Industrial Applications and Services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
20, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2 of 4</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Your
disclosure highlighting that Mango ED features ingredients contained in &ldquo;FDA- approved drugs&rdquo; suggests that this formulation
is safe. To the extent that you highlight that your formulation contains ingredients found in FDA-approved drugs, please revise to provide
equally prominent disclosure that these approvals do not mean that these ingredients will prove safe when combined into a single formulation
to treat ED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
The Company has revised the disclosures in Amendment No. 2 to clarify that just because the ingredients used in the Company&rsquo;s Mango
Ed product are FDA approved, that does not mean that these ingredients will prove safe when combined into a single formulation to treat
ED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Competition
and Competitive Advantages, page 3</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. On
page 3 you state that you are competing with companies which seek to sell Tadalafil in an oral disintegrating tablet. Please clarify
whether other companies are currently selling oral disintegrating tables for ED, including ones containing Tadalafil. Additionally, please
disclose whether your product formulation could be replicated by other companies.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
In Amendment No. 2, we have clarified that we are aware of other companies that are currently selling oral disintegrating tables for
ED, including ones containing Tadalafil and clarified that our product formulation could be replicated by other companies. We have also
included a new risk factor entitled &ldquo;<I>The main ingredients of our Mango ED product are publicly disclosed and separately our
Mango ED product is being specially compounded for the customer by a pharmacist with a physician's prescription, and as a result,
our Mango ED product formula can be replicated by other companies</I>&rdquo; describing the risks associated with the forgoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory
Environment, page 3</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. On
page 4, as well as page 51, you broadly cite &ldquo;scientific literature&rdquo; and &ldquo;previous clinical studies&rdquo; to support
the performance of the planned Mango ED product. Please revise your Business section to identify and discuss the literature and clinical
studies that you highlight in your Summary.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
We have revised Amendment No. 2 to reference the specific &ldquo;scientific literature&rdquo; and &ldquo;previous clinical studies&rdquo;
that support the performance of our Mango ED product</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Industrial Applications and Services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
20, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3 of 4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. We
refer to your disclosure on page 4 concerning FDA objection to any promotional activities, including those involving testimonials and
surrogates, absent substantial evidence derived from adequate and well-controlled clinical trials. Accordingly, please revise to clarify
whether you will be able to legally conduct any promotional activities for Mango ED, including activities involving the use of testimonials
and surrogates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
&#9;We have revised the disclosure in Amendment No. 2 to clarify that while the FDA will object to any promotional activity (including
through testimonials and surrogates) that is &lsquo;false or misleading in any particular way, we believe we can legally conduct truthful
and nonmisleading promotional activities &ndash; including activities involving the use of testimonials and surrogates &ndash; with more
limited claims that do not require substantial evidence derived from adequate and well-controlled clinical trials. For example, we can
market our Mango ED product based on claims that it employs a sublingual delivery mechanism, because such mechanisms generally allow
for a faster rate of drug absorption, without indicating that our planned drug has or may have the designed effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Please
explain your basis for stating that sublingual sildenafil &ldquo;typically functions in a similar way as tadalafil&rdquo; which is the
primary ingredient in your planned Mango ED product.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
Note, we have removed the references to sublingual sildenafil in Amendment No. 2 and as such, believe there is no need to further explain
such reference in the current draft.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Selected
Risks Associated with Our Company, page 6</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. We
note your revisions in response to prior comment 16 and refer to your website at https://www.mangorx.com/. Please tell us whether the
testimonials and the performance claims listed below concerning your planned product meet the Section 503A conditions under which compounded
human drug products are exempt from the FFDCA Act sections on FDA approval. We refer to the statements that Mango ED:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>is &ldquo;a fast-acting ED treatment;&rdquo;</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>has &ldquo;fast acting performance;&rdquo;</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;lasts up to 36 hours&rdquo; and</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&#9679;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;typically begins working in as little as 10 minutes.&rdquo;</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
While we believe that these claims do not implicate any of the conditions for qualifying for the exemptions under Section 503A &mdash;
none of the 503A conditions pertain to marketing or promotion of compounded drugs, and we further note that the Supreme Court struck
down the restrictions in Section 503A that pertained to promotional practices (<I>See Thompson v. Western States Medical Center</I>,
535 U.S. 357 (2002)), we have regardless revised and updated our website to remove statements that Mango ED: (a) is &ldquo;a fast-acting
ED treatment;&rdquo; (b) has &ldquo;fast acting performance;&rdquo; (c) &ldquo;lasts up to 36 hours&rdquo; and (d) &ldquo;typically begins
working in as little as 10 minutes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office of Industrial Applications and Services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
20, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 4 of 4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Managements
Discussion and Analysis of Financial Condition and Results of Operations</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Critical
Accounting Policies and Estimates, page 46</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. We
acknowledge your response to prior comment 18, and your revised disclosures.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
further expand your disclosure to clarify your accounting policy for warrants issued as part of a unit. For example, warrants may be
treated as equity classified instruments, or liability classified instruments that do not qualify for equity classification. You disclose
throughout your document that you issued restricted common stock to certain managers and other related parties. Revise your critical
accounting policy disclosure to address how you accounted for these shares, including how you determined their fair values. Once you
have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your
equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the initial public
offering and the estimated offering price. This information will help facilitate our review of your accounting for equity issuances including
stock compensation and beneficial conversion features. Please discuss with the staff how to submit your response.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
We have updated the &ldquo;Critical Accounting Policies and Estimates&rdquo; section in Amendment No. 2 to expand our disclosure to clarify
that the warrants included as part of the units which were sold were classified as equity instruments and to address how we accounted
for shares issued to management, including how we determined their fair values thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company will provide a response to the remainder of this comment once it has an estimated offering price or range, explaining
how it determined the fair value of the common stock underlying the Company&rsquo;s equity issuances and the reasons for any differences
between the recent valuations of the Company&rsquo;s common stock leading up to the IPO and the estimated offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business,
page 47</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. On
page 48, you provide a visual depiction of the evaluation and purchasing process. In the fifth step, you note that &ldquo;the prescription
is sent to our TX based partner pharmacy, Epiq Scripts, where it is filled and shipped.&rdquo; On page 2, you state that &ldquo;we initially
plan to focus our sales in the 21 states where our related party pharmacy is licensed and <I>where it is located</I>, with the goal of
eventually undertaking sales across all 50 states, pending licensing approvals of our related party pharmacy&rdquo; (emphasis added).
Please clarify whether Epiq Scripts is solely located in Texas, or whether it is located in each state or territory in which it receives
licensure.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
We have clarified in Amendment No. 2 that although Epiq Scripts is physically located in Texas, it can ship products to customers in
each state in which it holds licenses (currently 30 states), and have further removed the prior references to the Company only planning
to focus on states where Epiq Scripts is &lsquo;located&rsquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Unaudited
Financial Statements, page F-13</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10. Please
tell us why you believe that the labels &ldquo;Issuance of Common Stock for Cash&rdquo; presented in your Statement of Changes in Stockholders&rsquo;
deficit, and &ldquo;Sales of common stock for cash&rdquo; presented in your Statement of Cash Flows are appropriate, given that the transaction
the amounts were raised in was a private placement unit offering. Please revise as appropriate.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSE</U></B>:
We have revised the references to &ldquo;Issuance of Common Stock for Cash&rdquo; presented in our Statement of Changes in Stockholders&rsquo;
deficit, and &ldquo;Sales of common stock for cash&rdquo; presented in our Statement of Cash Flows to reference &ldquo;Units&rdquo; instead
of &ldquo;Common Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jacob Cohen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    Cohen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formdrsltr_001.jpg
<TEXT>
begin 644 formdrsltr_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ .\# 2(  A$! Q$!_\0
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ME9%N8F+JI)=(UE:/&)5C8!E+Q'$D1(SA)51R0P"DJ< %BBBB@ HHHH ****
M"BBB@ HHHH _,'X=?\%FO^"9_P 6?CII/[-7P[_:G\+^)_CAKGC/5OA]I7P_
MLO"7Q)AU*\\8:&UP-5T5+Z]\&6NC)-91VMS//-+J4=JD,$C&<,NVO%?VF/\
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M;KR7+VD?B2Y,'BW_  0?_P"#>?X5_P#!1OX#:U^UC^TY\4O''AGX577CK7O
M'@KX:_">70M!UWQ*/!MG8V_B;Q!XN\8:QH>O6&CZ7_;U[)9VVA:/H,$EQ-I>
MIO+);1K9O> ']JO[(/\ P6B_X)O?MQZ[_P (;\!?VCM O/B*T-Q<V_PP\=:3
MKGPW^(6I06\BQJ^@^&_&6GZ3/XHEN"X:WL_#,NL7Y0,\MK$%-:/P _X++?\
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M/^#7>=(? G_!7\2!DW_L2%D\P"#<HTOXJP9(G:(PG?=0_+.(GPV=N>#\_?\
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
